Children in Mexico living with the complex genetic disease Alagille syndrome have limited access to essential care, including confirmatory genetic testing at diagnosis and,…
News
The European Medicines Agency (EMA) has granted orphan drug designation to Suzhou Ribo Life Science’s experimental therapy RBD1016 for hepatitis D. The EMA gives…
CHOLANGITIS
NewsThis year, it’s ‘hope into action’ for PSC Awareness Day
Oct. 29 is Global PSC Awareness Day, and advocates around the world are joining forces to shine a light on primary sclerosing cholangitis (PSC)…
CHOLESTASIS
News2 simple nutrients may be effective new screening tool for ICP
A new study has identified two dietary nutrients, choline and dimethylglycine, as effective potential biomarkers for diagnosing and monitoring intrahepatic cholestasis of pregnancy (ICP).
FATTY LIVER DISEASE
NewsLong-term ketogenic diet may cause fatty liver disease, per mouse study
A long-term ketogenic diet, which favors fats over carbs, may promote weight loss, but it can also cause fatty liver disease and blood sugar…
BILIARY ATRESIA
NewsPotential biliary atresia treatment AX-0810 to enter clinical testing
AX-0810, an experimental medication Proqr Therapeutics is developing for biliary atresia and another liver disease called primary sclerosing cholangitis (PSC), is about to…
Kezar Life Sciences has hit a roadblock in plans to develop zetomipzomib, its experimental treatment for autoimmune hepatitis (AIH). The company has…
CHOLANGITIS
NewsSeladelpar approved in Canada as Lyvdelzi to treat adults with PBC
Health Canada has conditionally approved Gilead Sciences’ seladelpar — to be marketed in the country under the brand name Lyvdelzi — as a second-line…
CHOLESTASIS
NewsItching was main sign of teen’s liver disease: Case report
Itching was the main symptom leading to the diagnosis of progressive familial intrahepatic cholestasis (PFIC) type 3 in a teenage boy in Portugal, a…
FATTY LIVER DISEASE
NewsNew Helix dataset aims to accelerate liver disease research
A new dataset from genomics company Helix aims to accelerate research into metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease.
Recent Posts
- My son reaches the pedals on his big boy bike, and shows me I can, too
- Putting out the fires of inflammation in liver disease
- Change is good, but in life with MASH, it’s important to start small
- It turns out that having great friends is good for my health
- With Alagille syndrome, summer fun comes with a summer caution